Mayo Clinic: Lymphoma, Non-Hodgkin trials

The registry lists 18 Lymphoma, Non-Hodgkin studies with Mayo Clinic as lead sponsor. 3 are open to participants now and 7 have results posted.

Early Phase 1 2Phase 1 9Phase 2 8Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Wisconsin Ginseng for Decreasing Cancer Related FatigueRecruitingNCT06395441Phase 3
• Evaluation of Lymphoma Prognosis and Survivorship in Recently Diagnosed Patients, LEO StudyEnrolling by invitationNCT04996706
• Family Study of Lymphoproliferative DisordersRecruitingNCT00626496
• Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell LymphomaTerminatedNCT03075553Phase 2Results posted
• Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin LymphomaCompletedNCT03035331Phase 1/2Results posted
• Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01261247Phase 2Results posted
• Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT01075321Phase 1/2Results posted
• Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin LymphomaCompletedNCT00918333Phase 1/2Results posted
• Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin LymphomaCompletedNCT00784927Phase 2Results posted
• Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin LymphomaCompletedNCT00438880Phase 1/2Results posted
• Low-Dose Selinexor and Choline Salicylate for Non-Hodgkin or Hodgkin Lymphoma, Histiocytic/Dendritic Cell Neoplasm, or Relapsed or Refractory Multiple MyelomaCompletedNCT04640779Phase 1
• Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerTerminatedNCT03432741Phase 1
• Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 TrialCompletedNCT03003546Phase 1
• Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaCompletedNCT02652715Not applicable
• Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin LymphomaWithdrawnNCT02281279Phase 1/2
• Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01719250Early Phase 1
• Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin LymphomaCompletedNCT01239875Early Phase 1
• Interleukin-12 Plus Rituximab in Treating Patients With Non-Hodgkin's LymphomaCompletedNCT00004260Phase 1